文献速递肾小球疾病

他克莫司单药与泼尼松龙单药治疗成人初发微小病变肾病的随机对照试验

Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease: A Multicenter, Randomized, Controlled Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-01-17

本研究为多中心、前瞻性、开放标签、随机对照试验,纳入英国6个肾脏病中心的成人初发微小病变肾病伴肾病综合征患者,比较口服他克莫司(0.05 mg/kg 每日两次)与泼尼松龙(1 mg/kg 每日,最大60 mg/日)治疗8周完全缓解率。结果显示两组8周、16周、26周完全缓解率及复发率均无显著差异。他克莫司单药可作为希望避免激素治疗的患者的有效替代选择。

要点

  • 他克莫司单药与泼尼松龙单药在8周完全缓解率无显著差异(68% vs 84%,P=0.32)。
  • 16周和26周完全缓解率及复发率两组亦无显著差异。
  • 他克莫司单药可作为希望避免激素治疗的成人微小病变肾病患者的替代选择。

核心结论

  • 他克莫司单药治疗成人初发微小病变肾病可有效替代激素治疗,尤其适用于希望避免激素的患者。

研究设计与样本

  • 多中心、前瞻性、开放标签、随机对照试验,纳入英国6个肾脏病中心的成人初发微小病变肾病伴肾病综合征患者,随机接受口服他克莫司0.05 mg/kg每日两次或泼尼松龙1 mg/kg每日(最大60 mg/日)。

主要发现

  • 8周完全缓解率:泼尼松龙组21/25(84%),他克莫司组17/25(68%),P=0.32,差值16%(95%CI -11%至40%)。
  • 16周完全缓解率:泼尼松龙组23/25(92%),他克莫司组19/25(76%),P=0.25,差值16%(95%CI -8%至38%)。
  • 26周完全缓解率:泼尼松龙组23/25(92%),他克莫司组22/25(88%),P=0.99,差值4%(95%CI -17%至25%)。
  • 达到完全缓解患者的复发率:泼尼松龙组17/23(74%),他克莫司组16/22(73%),P=0.99;完全缓解至复发时间无显著差异。

临床怎么用

  • 对于成人初发微小病变肾病且希望避免激素治疗的患者,可考虑他克莫司单药治疗。

局限性

  • 开放标签设计可能引入偏倚;样本量较小(每组25例);未报告激素相关不良反应的详细数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Minimal change disease is an important cause of nephrotic syndrome in adults. Corticosteroids are first-line therapy for minimal change disease, but a prolonged course of treatment is often required and relapse rates are high. Patients with minimal change disease are therefore often exposed to high cumulative corticosteroid doses and are at risk of associated adverse effects. This study investigated whether tacrolimus monotherapy without corticosteroids would be effective for the treatment of de novo minimal change disease. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a multicenter, prospective, open-label, randomized, controlled trial involving six nephrology units across the United Kingdom. Adult patients with first presentation of minimal change disease and nephrotic syndrome were randomized to treatment with either oral tacrolimus at 0.05 mg/kg twice daily, or prednisolone at 1 mg/kg daily up to 60 mg daily. The primary outcome was complete remission of nephrotic syndrome after 8 weeks of therapy. Secondary outcomes included remission of nephrotic syndrome at 16 and 26 weeks, rates of relapse of nephrotic syndrome, and changes from baseline kidney function. RESULTS: There were no significant differences between the tacrolimus and prednisolone treatment cohorts in the proportion of patients in complete remission at 8 weeks (21 out of 25 [84%] for prednisolone and 17 out of 25 [68%] for tacrolimus cohorts; P=0.32; difference in remission rates was 16%; 95% confidence interval [95% CI], -11% to 40%), 16 weeks (23 out of 25 [92%] for prednisolone and 19 out of 25 [76%] for tacrolimus cohorts; P=0.25; difference in remission rates was 16%; 95% CI, -8% to 38%), or 26 weeks (23 out of 25 [92%] for prednisolone and 22 out of 25 [88%] for tacrolimus cohorts; P=0.99; difference in remission rates was 4%; 95% CI, -17% to 25%). There was no significant difference in relapse rates (17 out of 23 [74%] for prednisolone and 16 out of 22 [73%] for tacrolimus cohorts) for patients in each group who achieved complete remission (P=0.99) or in the time from complete remission to relapse. CONCLUSIONS: Tacrolimus monotherapy can be effective alternative treatment for patients wishing to avoid steroid therapy for minimal change disease. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2020_01_16_CJN06180519.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Medjeral-Thomas NR, Lawrence C, Condon M, et al. Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease: A Multicenter, Randomized, Controlled Trial. Clin J Am Soc Nephrol. 2020. PMID: 31953303. doi:10.2215/CJN.06180519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。